A nano-PROTAC on the horizon: combining targeted protein degradation and ferroptosis for advanced prostate cancer

A new study from Wuhan University and the Renmin Hospital of Wuhan University has reported a promising preclinical strategy for advanced prostate cancer, especially castration-resistant prostate cancer (CRPC). The work was published online in Angewandte Chemie International Edition, one of the leading international journals in chemistry.
The study describes a new nano-PROTAC platform designed to attack prostate cancer through two linked mechanisms at once: targeted protein degradation and ferroptosis sensitization.

The core idea is to improve the delivery and effectiveness of ARV-771, a PROTAC compound that can trigger the degradation of BRD4, a protein involved in cancer growth and androgen receptor signaling. PROTAC drugs are a powerful concept, but they often face practical problems such as poor water solubility, limited stability in the body, and weak targeting to tumors. To solve these issues, the researchers built a nanoplatform called ARV@MIL-HA-ss-HA(Note: a simple, fantastic name!), using the iron-based metal-organic framework MIL-101 as a carrier.

This carrier does more than transport the drug. MIL-101 also acts as a nanozyme, meaning it has enzyme-like activity. In the tumor environment, it can help generate hydroxyl radicals from hydrogen peroxide and reduce glutathione levels, both of which push cancer cells toward ferroptosis, a form of iron-dependent cell death. At the same time, the surface of the nanoplatform is coated with hyaluronic acid linked by disulfide bonds. This helps the system target CD44, a receptor often overexpressed on tumor cells, and also makes the drug release responsive to the high glutathione levels inside cancer cells.

The result is a dual-action system. After reaching the tumor, the nanoplatform releases ARV-771, which degrades BRD4 and weakens tumor growth signals. At the same time, the MIL-101 component promotes ferroptosis and makes the cells even more sensitive to death. According to the study, this combination produced strong antitumor activity in cell experiments and animal models, with better tumor accumulation, effective BRD4 degradation, enhanced ferroptosis, and acceptable biosafety.

The study is important because CRPC remains one of the hardest forms of prostate cancer to treat. Once prostate cancer becomes resistant to castration-based therapy, treatment options become limited and resistance to drugs is common. By combining PROTAC technology with nanozyme-driven ferroptosis, the researchers created a platform that may help overcome that resistance in a more effective way than either approach alone.

Source.